Detection of Viral Citrullinated Peptide Antibodies Directed Against EBV or VCP: In Early Rheumatoid Arthritis Patients of Indian Origin

ABSTRACT

Aim: Study was undertaken to analyze the frequency of anti-viral citrullinated peptide (anti-VCP) antibodies in sera from patients with early rheumatoid arthritis (ERA).

Materials and Methods: Viral citrullinated peptide (VCP) and Epstein-Barr nuclear antigen (EBNA-1) peptide were commercially prepared and antibodies to these were determined in 25 patients of ERA, 40 disease control patients constituting 25 rheumatoid arthritis (RA), 7 systemic lupus erythematosus (SLE), 2 scleroderma, 1 spondyloarthritis (SpA), 1 juvenile rheumatoid arthritis (JRA), 1 osteoarthritis (OA), 1 psoriatic arthritis (PsA), 1 undifferentiated arthritis (UA), and 1 gout and 25 healthy controls (HCs) were taken for comparison. In-house ELISA was established for both the antibodies while cyclic citrullinated peptide (CCP) antibody was detected by commercial ELISA kit.

Results: Significant increase in VCP antibody by ERA and disease controls than healthy normal was observed. VCP IgM antibody was significantly increased in RA patients than HC. The presence of VCP antibody signifies a good marker for ERA. We observed significant difference in the VCP IgG and IgM antibody when compared to EBNA-1. In-house ELISA established for EBNA-1 and VCP antibodies showed low sensitivity but 96% specificity.

Conclusions: We observed that sera from early RA patients reacted to the deiminated protein encoded by Epstain Barr Virus (EBV). Thus a possible role of virus in inducing an anti-citrullinated peptide antibody (ACPA) response reveals viral etiology in this disease.

Keywords

Anti-viral citrullinated peptides/antibodies - ERA - EBNA-1 - ELISA

• REFERENCES

• 1 Yao QY, Tierney RJ, Croom-Carter D, Dukers D, Cooper GM, Ellis CJ, et al. Frequency of multiple Epstein–Barr virus infections in T cell immunocompromised individuals. J Virol 1996;8:4884-94.
• 2 Kutty SN, Christoph K, Sabrina H, Stefan C, Harald B, Rikard H. Antibodies to citrullinated proteins: Molecular interactions and arthritogenicity. Immunol Rev 2010;233:9-33.
• 3 Aslpaugh MA, Tan EM. Serum antibody in rheumatoid arthritis reactive with a cell-associated antigen. Demonstration by precipitation and immunofluorescence. Arthritis Rheum 1976;19:711-9.
• 4 Alspaugh MA, Jensen FC, Rabin H, Tan EM. Lymphocytes transformed by Epstein-Barr virus. Induction of nuclear antigen reactive with antibody in rheumatoid arthritis. J Exp Med 1978;147:1018-27.
• 5 Lotz M, Roudier J. Epstein-Barr virus and rheumatoid arthritis: Cellular and Molecular aspects. Rheumatol Int 1989;9:147-52.
• 6 Gartner BC, Hess RD, Bandt D, Kruse A, Rethwilm A, Roemer K, et al. Evaluation of four commercially available Epstein-Barr Virus enzyme Immunoassays with an immunoflourescence assay as the reference method. Clin Diagn Lab Immunol 2003;10:78-82.
• 7 Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorani P. Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol 2006;33:647-51.
• 8 Alspaugh MA, Henle G, Lennette ET, Henle W. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients of Rheumatoid arthritis. J Clin Invest 1981;67:134-40.
• 9 Billings PB, Hoch SO, White PJ, Carson DA, Vaughan JH. Antibodies to Epstain-Barr virus nuclear antigen and to rheumatoid arthritis nuclear antigen identify the same polypeptide. Proc Natl Acad Sci USA 1983;80:7104-8.
• 10 Venable PJ, Roffe LM, Erhardt CC, Maini RN, Edwards JM, Porter AB. Titers of antibodies to RANA in rheumatoid arthritis and normal sera: Relationship to Epstein-Barr virus infection. Arthritis Rheum 1981;24:1459-64.
• 11 Anizilotti C, Riente L, Pratesi F, Chimenti D, Delle Sedie A, Bombardieri S, et al. IgG, IgA, IgM antibodies to a viral citrullinated peptide in patients affected by rheumatoid arthritis, chronic arthritides and connective tissue disorders. Rheumatology (Oxford) 2007;46:1579-82.
• 12 Rea TD, Ashley RA, Russo JE, Bucheald DS. A systematic study of Epstein-Barr Virus serological assays following acute infection. Am J Clin Pathol 2002;117:156-61.
• 13 Costenbader KH, Karlson EW. Epstein- Barr virus and rheumatoid arthritis: Is there a link. Arthritis Research and Therapy 2006;8:1-7.
• 14 Blaschke S, Schwarz G, Monke D, Binder L, Muller G, Reuss-Borst MJ. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells and synovial membranes of patients with rheumatoid arthritis. J Rheumatol 2000;27:866-73.
• 15 Pratesi F, Tommasi C, Anzilotti C, Chimenti D,Migliorini P. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006;5493:733-41.
• 16 Uysal H, Bockermann R, Kutty SN, Sehnert B, Bajtner E, Engström A, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen Type II in experimental arthritis. J Exp Med 2009;206:449-62.
• 17 Ollier W. Rheumatoid arthritis and Epstein-Barr virus: A case of living with the enemy. Ann Rheum Dis 2000;59:497-9.
• 18 Toussirot E, Roudie J. Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: An update. Joint Bone Spine 2007;74:418-26.
• 19 Catyalano MA, Carson DA, Slovin SF, Richman DD, Vaughan JH. Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. Proc Natl Acad Sci USA 1979;76:5825-8.